Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
AAPS PharmSciTech. 2010 Jun;11(2):859-69. doi: 10.1208/s12249-010-9445-5. Epub 2010 May 19.
This study aimed at preparation of a sustained-release steroidal treatment for chronic inflammatory conditions, such as rheumatoid arthritis. To achieve such a goal, biodegradable poly-lactide-co-glycolide prednisolone-loaded microspheres were prepared using o/w emulsion solvent evaporation method. Formulation parameters were adjusted so as to optimize the microsphere characteristics. The prepared microspheres exhibited smooth and intact surfaces, with average size range not exceeding 65 microm. The encapsulation efficiency percent of most microsphere formulations fell within the range of 25-68%. Drug release from these microspheres took place over 4 weeks, with near-to-zero-order patterns. Two successful formulations were chosen for the treatment of unilateral arthritis, induced in mice using Freund's complete adjuvant (FCA). Inflammatory signs of adjuvant arthritis included severe swelling of the FCA-injected limbs, in addition to many histopathological lesions. These included inflammatory cell infiltration, synovial hyperplasia, cartilage, and bone erosion. Parenteral administration of the selected formulae dramatically reduced the swelling of the FCA-injected limbs. In addition, histological examination revealed that the microsphere treatment protocol efficiently protected cartilages and bones of mice, injected with FCA initial and booster doses, from erosion. These results could not be achieved by a single prednisolone dose of 5 mg/kg.
本研究旨在制备一种用于治疗慢性炎症性疾病(如类风湿性关节炎)的甾体缓释治疗方法。为了实现这一目标,采用 o/w 乳液溶剂蒸发法制备了可生物降解的聚丙交酯-乙交酯载泼尼松龙微球。通过调整制剂参数来优化微球特性。所制备的微球表面光滑完整,平均粒径不超过 65 微米。大多数微球制剂的包封效率百分比在 25-68%范围内。这些微球中的药物在 4 周内释放,呈近零级模式。选择两种成功的制剂用于治疗弗氏完全佐剂(FCA)诱导的单侧关节炎。佐剂性关节炎的炎症表现包括 FCA 注射肢体的严重肿胀,以及许多组织病理学病变。这些病变包括炎症细胞浸润、滑膜增生、软骨和骨侵蚀。选择的配方的肠胃外给药可显著减轻 FCA 注射肢体的肿胀。此外,组织学检查显示,微球治疗方案有效地保护了接受 FCA 初始和加强剂量注射的小鼠的软骨和骨骼免受侵蚀。这一效果不能通过 5mg/kg 的单剂量泼尼松龙来实现。